# Alaska Permanent Fund

> Alaska Permanent Fund is a VC fund backing Biotechnology and Therapeutics. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Juneau, United States
- Total investments: 17
- Last investment: Feb 2024
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/alaska-permanent-fund-corporation
- Website: http://www.apfc.org
- Facebook: https://www.facebook.com/AlaskaPFC

Alaska Permanent Fund is a VC fund in Juneau focused on Biotechnology and Therapeutics. The Alaska Permanent Fund is a constitutionally established permanent fund managed by a state-owned corporation, the Alaska Permanent Fund

## Contacts

5 contacts available for Alaska Permanent Fund. Shizune tracks 6 team members at Alaska Permanent Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alaska-permanent-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 47% |
| Therapeutics | 6 | 35% |
| Medical | 5 | 29% |
| Health Care | 4 | 24% |
| Life Science | 2 | 12% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 35% |
| Series A | 4 | 24% |
| Series C | 3 | 18% |
| Series D | 1 | 6% |
| Series E | 1 | 6% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jay Hammond | Founder | 0 | https://shizune.co/investors/profile/jay-hammond-e882 |
| Travis Brown | Member of Private Equity & Special Opportunities | 0 | https://shizune.co/investors/profile/travis-brown-2 |
| Angela M. Rodell | Chief Executive Officer | 0 | https://shizune.co/investors/profile/angela-m-rodell |
| Marcus Frampton | Head of Real Assets | 0 | https://shizune.co/investors/profile/marcus-frampton |
| Sebastian Vadakumcherry | Chief Risk & Compliance Officer | 0 | https://shizune.co/investors/profile/sebastian-vadakumcherry-f2ea |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kenai Therapeutics | Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's. | $82M | Series A | Feb 29, 2024 |  |
| Tessera Therapeutics | Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine,building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | $300M | Series C | Apr 19, 2022 |  |
| NorthLink Aviation | NorthLink Aviation holds a 55-year lease for the 120-acre South Park Campus and is developing critical airport infrastructure at the site to support growing cargo volumes at ANC. |  | Venture - Series Unknown | Dec 01, 2021 |  |
| Generate Biomedicines | Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. | $370M | Series B | Nov 18, 2021 |  |
| Repertoire Immune Medicines | Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15. | $189M | Series B | Apr 13, 2021 |  |
| Tessera Therapeutics | Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine,building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | $230M | Series B | Jan 12, 2021 |  |
| Indigo | Indigo is an agricultural technology company that focuses on improving the sustainability and productivity of agriculture. The company focuses on the microbes that have evolved in conjunction with plants over billions of years to optimize their health and maximize their productivity. Indigo believes we are at the forefront of something that servesthe needs of both farmers and consumers. For farmers, the yield benefits will help improve grower profitability while increasing our capacity to feed a growing population. For consumers, Indigo can begin to make fundamental changes in how our food is grown; like being more efficient with water, and reducing the use of nitrogen fertilizer and pesticides over time. | $360M | Series F | Aug 03, 2020 |  |
| Sana Biotechnology | Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients.Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.The company is a team of scientists, clinicians and biotechnologyveterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases. | $700M | Series A | Jun 23, 2020 |  |
| Indigo | Indigo is an agricultural technology company that focuses on improving the sustainability and productivity of agriculture. The company focuses on the microbes that have evolved in conjunction with plants over billions of years to optimize their health and maximize their productivity. Indigo believes we are at the forefront of something that servesthe needs of both farmers and consumers. For farmers, the yield benefits will help improve grower profitability while increasing our capacity to feed a growing population. For consumers, Indigo can begin to make fundamental changes in how our food is grown; like being more efficient with water, and reducing the use of nitrogen fertilizer and pesticides over time. | $250M | Series E | Sep 18, 2018 |  |
| Codiak Biosciences | Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak hasdeveloped its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. | $76.5M | Series C | Nov 29, 2017 |  |

10 of 17 investments shown.

## Co-investors
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 14 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 8 deals together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 4 deals together
- [Baillie Gifford](https://shizune.co/investors/profile/baillie-gifford) — VC Fund, 3 deals together
- [CEAS Investments](https://shizune.co/investors/profile/ceas-investments) — VC Fund, 3 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Alaska Permanent Fund invest in?

Alaska Permanent Fund invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alaska Permanent Fund?

Public channels for Alaska Permanent Fund include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alaska Permanent Fund?

The team at Alaska Permanent Fund includes Jay Hammond (Founder), Travis Brown (Member of Private Equity & Special Opportunities) and Angela M. Rodell (Chief Executive Officer), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co